FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200594359> ?p ?o ?g. }

• W4200594359 endingPage "P216" @default.
• W4200594359 startingPage "P216" @default.
• W4200594359 abstract "Abstract The Hippo signaling cascade is an important pathway that plays a role in controlling cell proliferation and limiting apoptosis, but when dysregulated can contribute to cancer initiation, progression, and therapeutic resistance. The TEAD family of transcription factors, in conjunction with YAP1 or WWTR1/TAZ, are regulated by Hippo pathway signaling and modulate cell growth and proliferation. IK-930 inhibits the growth of TEAD-dependent human cancer xenografts. By exploiting synthetic lethality, the IK-930 single agent activity in TEAD-dependent cancers could expand to other indications upon inhibition of certain oncogenic pathways. Literature indicates that activation of TEAD-dependent transcription by other oncogenes such as mutant EGFR or KRAS mediates resistance to multiple targeted therapies. Additionally, genetic loss of YAP1 leads to increased apoptosis in osimertinib and trametinib treated mutant EGFR NSCLC cell lines (Kurppa, 2020). Here, we present preclinical data that support the use of IK-930 combination therapies to enhance anti-tumor impact of EGFR and MEK blockade in mutant EGFR NSCLC, or with MEK inhibition in several BRAF and KRAS mutant cancers. In these studies, EGFR and MEK1/2 were inhibited and IK-930 used to enhance anti-tumor activity in EGFR-mutant NSCLC cells. These NSCLC cell lines that are largely insensitive to osimertinib and/or trametinib, were observed to have a marked increase in apoptosis in vitro when treated with the combination of osimertinib, trametinib, and IK-930. We also observed increased nuclear accumulation of YAP1 after treatment of NSCLC cells with osimertinib alone, or osimertinib and trametinib and upregulation of TEAD-dependent transcription. In NSCLC xenografts, the combination of osimertinib and IK-930 prevented tumor growth and the triple combination of osimertinib, IK-930, and trametinib drove complete tumor regression and demonstrated greater efficacy than any single agent or double combination. A second set of studies tested the synthetic lethality effect of IK-930 and MEK inhibition in RAF- and RAS-mutant tumors. The combination of TEAD inhibition with MEK inhibition enhanced apoptosis in several KRAS-mutant NSCLC, PDAC, CRC KRAS-mutant cell lines and BRAF-mutant melanoma. The combination of trametinib and IK-930 prevented tumor growth in these xenografts, where either single agent had either modest or little activity. In summary, the Hippo pathway has been implicated in multiple tumor types, including those with resistance mechanisms to EGFR and MEK blockade. IK-930-mediated TEAD inhibition has been investigated to suppress the bypass pathway activation mechanism to the targeted therapies. These data demonstrated the potential to further expand single agent patient benefit by combining IK-930 with MEK and/or EGFR inhibition in a wide variety of cancer indications, including mutant EGFR-driven NSCLC and mutant KRAS colon, lung, and pancreatic cancers. Taken together, these data are informing the clinical development plan and combination strategy for IK-930, a novel TEAD inhibitor. Citation Format: Benjamin Amidon, Hyejin Frosch, Sakeena Syed, Jill Cavanaugh, Chelsea Turcotte, Katie O'Callaghan, Prabitha Natarajan, Jeffrey Ecsedy, Karen McGovern, Alfredo Castro. IK-930 mediated TEAD inhibition decreases and delays tumor growth and enhances targeted apoptosis in lung and colon cancer xenografts when combined with MEK or EGFR inhibitors [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P216." @default.
• W4200594359 created "2021-12-31" @default.
• W4200594359 creator A5009763203 @default.
• W4200594359 creator A5011746083 @default.
• W4200594359 creator A5034271088 @default.
• W4200594359 creator A5053953098 @default.
• W4200594359 creator A5062871565 @default.
• W4200594359 creator A5068262293 @default.
• W4200594359 creator A5080700010 @default.
• W4200594359 creator A5082557041 @default.
• W4200594359 creator A5085672356 @default.
• W4200594359 creator A5088242427 @default.
• W4200594359 date "2021-12-01" @default.
• W4200594359 modified "2023-09-25" @default.
• W4200594359 title "Abstract P216: IK-930 mediated TEAD inhibition decreases and delays tumor growth and enhances targeted apoptosis in lung and colon cancer xenografts when combined with MEK or EGFR inhibitors" @default.
• W4200594359 doi "https://doi.org/10.1158/1535-7163.targ-21-p216" @default.
• W4200594359 hasPublicationYear "2021" @default.
• W4200594359 type Work @default.
• W4200594359 citedByCount "4" @default.
• W4200594359 countsByYear W42005943592022 @default.
• W4200594359 countsByYear W42005943592023 @default.
• W4200594359 crossrefType "journal-article" @default.
• W4200594359 hasAuthorship W4200594359A5009763203 @default.
• W4200594359 hasAuthorship W4200594359A5011746083 @default.
• W4200594359 hasAuthorship W4200594359A5034271088 @default.
• W4200594359 hasAuthorship W4200594359A5053953098 @default.
• W4200594359 hasAuthorship W4200594359A5062871565 @default.
• W4200594359 hasAuthorship W4200594359A5068262293 @default.
• W4200594359 hasAuthorship W4200594359A5080700010 @default.
• W4200594359 hasAuthorship W4200594359A5082557041 @default.
• W4200594359 hasAuthorship W4200594359A5085672356 @default.
• W4200594359 hasAuthorship W4200594359A5088242427 @default.
• W4200594359 hasConcept C104317684 @default.
• W4200594359 hasConcept C121608353 @default.
• W4200594359 hasConcept C126322002 @default.
• W4200594359 hasConcept C172512520 @default.
• W4200594359 hasConcept C190283241 @default.
• W4200594359 hasConcept C2777626846 @default.
• W4200594359 hasConcept C2778472372 @default.
• W4200594359 hasConcept C2780219982 @default.
• W4200594359 hasConcept C2781187634 @default.
• W4200594359 hasConcept C2781249067 @default.
• W4200594359 hasConcept C502942594 @default.
• W4200594359 hasConcept C526805850 @default.
• W4200594359 hasConcept C54355233 @default.
• W4200594359 hasConcept C55493867 @default.
• W4200594359 hasConcept C57074206 @default.
• W4200594359 hasConcept C62112901 @default.
• W4200594359 hasConcept C62478195 @default.
• W4200594359 hasConcept C71924100 @default.
• W4200594359 hasConcept C86339819 @default.
• W4200594359 hasConcept C86803240 @default.
• W4200594359 hasConcept C95444343 @default.
• W4200594359 hasConceptScore W4200594359C104317684 @default.
• W4200594359 hasConceptScore W4200594359C121608353 @default.
• W4200594359 hasConceptScore W4200594359C126322002 @default.
• W4200594359 hasConceptScore W4200594359C172512520 @default.
• W4200594359 hasConceptScore W4200594359C190283241 @default.
• W4200594359 hasConceptScore W4200594359C2777626846 @default.
• W4200594359 hasConceptScore W4200594359C2778472372 @default.
• W4200594359 hasConceptScore W4200594359C2780219982 @default.
• W4200594359 hasConceptScore W4200594359C2781187634 @default.
• W4200594359 hasConceptScore W4200594359C2781249067 @default.
• W4200594359 hasConceptScore W4200594359C502942594 @default.
• W4200594359 hasConceptScore W4200594359C526805850 @default.
• W4200594359 hasConceptScore W4200594359C54355233 @default.
• W4200594359 hasConceptScore W4200594359C55493867 @default.
• W4200594359 hasConceptScore W4200594359C57074206 @default.
• W4200594359 hasConceptScore W4200594359C62112901 @default.
• W4200594359 hasConceptScore W4200594359C62478195 @default.
• W4200594359 hasConceptScore W4200594359C71924100 @default.
• W4200594359 hasConceptScore W4200594359C86339819 @default.
• W4200594359 hasConceptScore W4200594359C86803240 @default.
• W4200594359 hasConceptScore W4200594359C95444343 @default.
• W4200594359 hasIssue "12_Supplement" @default.
• W4200594359 hasLocation W42005943591 @default.
• W4200594359 hasOpenAccess W4200594359 @default.
• W4200594359 hasPrimaryLocation W42005943591 @default.
• W4200594359 hasRelatedWork W2346079527 @default.
• W4200594359 hasRelatedWork W2727394583 @default.
• W4200594359 hasRelatedWork W2865458437 @default.
• W4200594359 hasRelatedWork W2920147611 @default.
• W4200594359 hasRelatedWork W2986966718 @default.
• W4200594359 hasRelatedWork W3022164378 @default.
• W4200594359 hasRelatedWork W4200594359 @default.
• W4200594359 hasRelatedWork W4361843741 @default.
• W4200594359 hasRelatedWork W4361843751 @default.
• W4200594359 hasRelatedWork W4367603508 @default.
• W4200594359 hasVolume "20" @default.
• W4200594359 isParatext "false" @default.
• W4200594359 isRetracted "false" @default.
• W4200594359 workType "article" @default.